Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 18, 2013Representatives Will Use Educational Tool for Up to 65,000 Physicians
Eisai and BusinessOne Technologies announced today that Eisai Inc. is using the Maestro Market Access Mobile™ application...
-
Nov 13, 2013BELVIQ® (lorcaserin HCl) CIV Data Featured in Five Abstracts to be Presented at ObesityWeek(SM) 2013
Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that five abstracts highlighting new data analyses from...
-
Nov 13, 2013Eisai to Convene Multidisciplinary Expert Panel in an Effort to Combat Growing Epidemic
A new survey conducted by Eisai Inc., in partnership with the Obesity Action Coalition (OAC) and The Obesity Society (TOS), reveals a...
-
Nov 8, 2013
Eisai Inc. announced today that ACIPHEX® Sprinkle™ Delayed-Release Capsules 5mg and 10mg will be available to eligible patients by...
-
Nov 7, 2013-- Collaboration to Focus on Global Commercialization and Development for Weight Management and Potential New Indications --
SAN DIEGO, CA and WOODCLIFF LAKE, NJ, November 7, 2013 – Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing...
-
Nov 1, 2013Award supports vital research to understand rare and severe form of epilepsy
The Child Neurology Foundation (CNF) and Eisai Inc. today announced that the first annual Michael SanInocencio Lennox-Gastaut Syndrome (LGS)...
-
Oct 15, 2013BELVIQ® Sales Force to Double in Size by December 2013
Eisai Inc. announced today that, as part of its long-term marketing strategy, the company will expand its sales force by adding more than 200...
-
Sep 12, 2013Eisai Launches BELVIQ® Patient Support Program Offering On-Line Tools to Enhance Weight Loss EffortsThe BELIEVE EVERYDAY SUPPORTSM Program Offers Customized Lifestyle Resources and Free Membership to Top Calorie Tracking App for Use by BELVIQ® (lorcaserin HCl) CIV Patients
Eisai Inc. today announced the availability of the BELIEVE EVERYDAY SUPPORTSM program to provide free, comprehensive support and savings for BELVIQ
-
Aug 29, 2013
Eisai Inc. announced that the company has recently entered into a non-exclusive licensing agreement in the United States with a manufacturer of...
-
Aug 19, 2013Epilepsy Drug Still Not Available to Patients 10 Months After FDA Approval
Eisai Inc. filed a petition today with the U.S. Court of Appeals for the District of Columbia asking the court to direct the Drug Enforcement...
-
Aug 15, 2013
Eisai Inc. announced today the launch of a new website to provide employers with an educational resource for information about obesity...
-
Jun 20, 2013
Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that data from the BELVIQ® (lorcaserin HCl) Phase 3...
-
Jun 14, 2013
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), announced today that data from the BELVIQ® (lorcaserin HCl) Phase 3...
-
Jun 13, 2013Former Secretary of State and Epilepsy Advocate Hillary Rodham Clinton to Speak as This Year's Guest of Honor
Eisai Inc. announced today its platinum level sponsorship of the Citizens United for Research in Epilepsy (CURE) 15th Annual Chicago Benefit...
Jun 7, 2013BELVIQ Available in U.S. Pharmacies within One WeekWOODCLIFF LAKE, NJ, June 7, 2013 /PRNewswire/ — Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States...
-
May 8, 2013
Eisai Inc. announced today that the U.S. Drug Enforcement Administration (DEA) has placed BELVIQ (pronounced BEL-VEEK) into Schedule IV of the...
-
Apr 18, 2013-- 4 Paws for Ability Service Dogs to Greet Visitors at Eisai Event Booth --
Woodcliff Lake, NJ - April 18, 2013 - Eisai Inc. announced today that it is a silver level sponsor of the Epilepsy Foundation's 7th Annual National Walk for Epilepsy, a family-oriented,...
-
Mar 26, 2013
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved ACIPHEX(®) Sprinkle™ Delayed-Release Capsules 5mg...
-
Dec 11, 2012
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) determined that Eisai has met the FDA's Written Request requirements...
-
Nov 30, 2012
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA)...
-
Nov 8, 2012Eisai Recognizes Inaugural LGS Awareness Day and Epilepsy Awareness Month with Launch of New Caregiver Support Video
With approximately two million people in the United States living with epilepsy, including a severe and rare form called Lennox-Gastaut syndrome...
-
Oct 22, 2012-- FYCOMPA is the First FDA-Approved Non-competitive AMPA Glutamate Receptor Antagonist --
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA (perampanel) as an adjunctive treatment for...
-
Aug 20, 2012
Eisai Inc. announced today that the results of two studies: "Evaluation of Adjunctive Perampanel in Patients with Refractory Partial Onset...
-
Jul 30, 2012Eisai Plans to Submit Applications for Marketing Approval throughout the Americas
WOODCLIFF LAKE, NJ, and SAN DIEGO, CA, July 30, 2012 -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Arena has transferred the BELVIQ® (lorcaserin hydrochloride)...
-
Jul 25, 2012
Eisai Inc. announced today that the results of the study, "Adjunctive Perampanel For Refractory Partial-Onset Seizures: Randomized Phase III...